Logo image of CLPT

CLEARPOINT NEURO INC (CLPT) Stock Fundamental Analysis

NASDAQ:CLPT - Nasdaq - US18507C1036 - Common Stock - Currency: USD

16.38  -0.34 (-2.03%)

After market: 16.38 0 (0%)

Fundamental Rating

4

CLPT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. While CLPT has a great health rating, there are worries on its profitability. CLPT is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLPT had negative earnings in the past year.
CLPT had a negative operating cash flow in the past year.
CLPT had negative earnings in each of the past 5 years.
In the past 5 years CLPT always reported negative operating cash flow.
CLPT Yearly Net Income VS EBIT VS OCF VS FCFCLPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

CLPT has a worse Return On Assets (-45.15%) than 65.24% of its industry peers.
The Return On Equity of CLPT (-62.57%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -45.15%
ROE -62.57%
ROIC N/A
ROA(3y)-34.46%
ROA(5y)-34.56%
ROE(3y)-59.48%
ROE(5y)-116.8%
ROIC(3y)N/A
ROIC(5y)N/A
CLPT Yearly ROA, ROE, ROICCLPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

CLPT's Gross Margin of 60.38% is in line compared to the rest of the industry. CLPT outperforms 58.29% of its industry peers.
In the last couple of years the Gross Margin of CLPT has declined.
The Profit Margin and Operating Margin are not available for CLPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.19%
GM growth 5Y-3.22%
CLPT Yearly Profit, Operating, Gross MarginsCLPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

7

2. Health

2.1 Basic Checks

CLPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLPT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CLPT has been increased compared to 5 years ago.
The debt/assets ratio for CLPT is higher compared to a year ago.
CLPT Yearly Shares OutstandingCLPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
CLPT Yearly Total Debt VS Total AssetsCLPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

CLPT has an Altman-Z score of 18.25. This indicates that CLPT is financially healthy and has little risk of bankruptcy at the moment.
CLPT's Altman-Z score of 18.25 is amongst the best of the industry. CLPT outperforms 94.12% of its industry peers.
There is no outstanding debt for CLPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.25
ROIC/WACCN/A
WACC8.99%
CLPT Yearly LT Debt VS Equity VS FCFCLPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

CLPT has a Current Ratio of 4.54. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CLPT (4.54) is better than 74.33% of its industry peers.
CLPT has a Quick Ratio of 3.61. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
CLPT's Quick ratio of 3.61 is fine compared to the rest of the industry. CLPT outperforms 72.19% of its industry peers.
Industry RankSector Rank
Current Ratio 4.54
Quick Ratio 3.61
CLPT Yearly Current Assets VS Current LiabilitesCLPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.33% over the past year.
The Revenue has grown by 36.39% in the past year. This is a very strong growth!
CLPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 26.65% yearly.
EPS 1Y (TTM)23.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)36.39%
Revenue growth 3Y23.14%
Revenue growth 5Y26.65%
Sales Q2Q%40.96%

3.2 Future

CLPT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.03% yearly.
CLPT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.76% yearly.
EPS Next Y24.53%
EPS Next 2Y15.86%
EPS Next 3Y12.03%
EPS Next 5YN/A
Revenue Next Year34.32%
Revenue Next 2Y27.94%
Revenue Next 3Y39.76%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLPT Yearly Revenue VS EstimatesCLPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
CLPT Yearly EPS VS EstimatesCLPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLPT Price Earnings VS Forward Price EarningsCLPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLPT Per share dataCLPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as CLPT's earnings are expected to grow with 12.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.86%
EPS Next 3Y12.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARPOINT NEURO INC

NASDAQ:CLPT (2/24/2025, 5:20:00 PM)

After market: 16.38 0 (0%)

16.38

-0.34 (-2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners33.28%
Inst Owner Change-87.7%
Ins Owners4.61%
Ins Owner Change-0.02%
Market Cap451.76M
Analysts84.44
Price Target22.78 (39.07%)
Short Float %2.57%
Short Ratio2.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.21%
Min EPS beat(2)-1.81%
Max EPS beat(2)20.24%
EPS beat(4)3
Avg EPS beat(4)11.06%
Min EPS beat(4)-1.81%
Max EPS beat(4)20.24%
EPS beat(8)5
Avg EPS beat(8)0.76%
EPS beat(12)8
Avg EPS beat(12)3.79%
EPS beat(16)10
Avg EPS beat(16)3.49%
Revenue beat(2)2
Avg Revenue beat(2)3.73%
Min Revenue beat(2)2.36%
Max Revenue beat(2)5.11%
Revenue beat(4)4
Avg Revenue beat(4)4.18%
Min Revenue beat(4)2.19%
Max Revenue beat(4)7.08%
Revenue beat(8)5
Avg Revenue beat(8)0.19%
Revenue beat(12)7
Avg Revenue beat(12)0.89%
Revenue beat(16)9
Avg Revenue beat(16)2.04%
PT rev (1m)36.73%
PT rev (3m)88.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2%
EPS NY rev (1m)0%
EPS NY rev (3m)1.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.85
P/FCF N/A
P/OCF N/A
P/B 15.58
P/tB 15.91
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS1.1
BVpS1.05
TBVpS1.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.15%
ROE -62.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.38%
FCFM N/A
ROA(3y)-34.46%
ROA(5y)-34.56%
ROE(3y)-59.48%
ROE(5y)-116.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.19%
GM growth 5Y-3.22%
F-Score5
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.92%
Cap/Sales 0.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.54
Quick Ratio 3.61
Altman-Z 18.25
F-Score5
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)251.1%
Cap/Depr(5y)202.61%
Cap/Sales(3y)3.68%
Cap/Sales(5y)3.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y24.53%
EPS Next 2Y15.86%
EPS Next 3Y12.03%
EPS Next 5YN/A
Revenue 1Y (TTM)36.39%
Revenue growth 3Y23.14%
Revenue growth 5Y26.65%
Sales Q2Q%40.96%
Revenue Next Year34.32%
Revenue Next 2Y27.94%
Revenue Next 3Y39.76%
Revenue Next 5YN/A
EBIT growth 1Y15.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.43%
EBIT Next 3Y24.6%
EBIT Next 5YN/A
FCF growth 1Y48.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.68%
OCF growth 3YN/A
OCF growth 5YN/A